Detalhe da pesquisa
1.
Combination therapy with pazopanib and tivantinib modulates VEGF and c-MET levels in refractory advanced solid tumors.
Invest New Drugs;
39(6): 1577-1586, 2021 12.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34180036
2.
Cabozantinib in patients with platinum-refractory metastatic urothelial carcinoma: an open-label, single-centre, phase 2 trial.
Lancet Oncol;
21(8): 1099-1109, 2020 08.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32645282
3.
Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma.
N Engl J Med;
374(2): 135-45, 2016 Jan 14.
Artigo
em Inglês
| MEDLINE
| ID: mdl-26536169
4.
Hepatocyte growth factor/MET in cancer progression and biomarker discovery.
Cancer Sci;
108(3): 296-307, 2017 Mar.
Artigo
em Inglês
| MEDLINE
| ID: mdl-28064454
5.
Targeting the hepatocyte growth factor/Met pathway in cancer.
Biochem Soc Trans;
45(4): 855-870, 2017 08 15.
Artigo
em Inglês
| MEDLINE
| ID: mdl-28673936
6.
Synergistic signaling of tumor cell invasiveness by hepatocyte growth factor and hypoxia.
J Biol Chem;
289(30): 20448-61, 2014 Jul 25.
Artigo
em Inglês
| MEDLINE
| ID: mdl-24914205
7.
Imaging the Met Receptor Tyrosine Kinase (Met) and Assessing Tumor Responses to a Met Tyrosine Kinase Inhibitor in Human Xenograft Mouse Models with a [99mTc] (AH-113018) or Cy 5** (AH-112543) Labeled Peptide.
Mol Imaging;
14: 499-515, 2015.
Artigo
em Inglês
| MEDLINE
| ID: mdl-26461980
8.
Preliminary evaluation of urinary soluble Met as a biomarker for urothelial carcinoma of the bladder.
J Transl Med;
12: 199, 2014 Oct 21.
Artigo
em Inglês
| MEDLINE
| ID: mdl-25335552
9.
Rilotumumab Resistance Acquired by Intracrine Hepatocyte Growth Factor Signaling.
Cancers (Basel);
15(2)2023 Jan 11.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36672409
10.
Molecular diagnosis and therapy of kidney cancer.
Annu Rev Med;
61: 329-43, 2010.
Artigo
em Inglês
| MEDLINE
| ID: mdl-20059341
11.
Inhibition of hypoxia inducible factor-2 transcription: isolation of active modulators from marine sponges.
J Nat Prod;
75(9): 1632-6, 2012 Sep 28.
Artigo
em Inglês
| MEDLINE
| ID: mdl-22928967
12.
Inhibition of HSP 90 is associated with potent anti-tumor activity in Papillary Renal Cell Carcinoma.
J Exp Clin Cancer Res;
41(1): 208, 2022 Jun 27.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35754026
13.
Regression of Human Breast Carcinoma in Nude Mice after Adsflt Gene Therapy Is Mediated by Tumor Vascular Endothelial Cell Apoptosis.
Cancers (Basel);
14(24)2022 Dec 14.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36551660
14.
Correction: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer.
PLoS One;
17(10): e0276211, 2022.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36215283
15.
Clinical Activity of Single-Agent Cabozantinib (XL184), a Multi-receptor Tyrosine Kinase Inhibitor, in Patients with Refractory Soft-Tissue Sarcomas.
Clin Cancer Res;
28(2): 279-288, 2022 01 15.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34716194
16.
Cabozantinib plus Nivolumab Phase I Expansion Study in Patients with Metastatic Urothelial Carcinoma Refractory to Immune Checkpoint Inhibitor Therapy.
Clin Cancer Res;
28(7): 1353-1362, 2022 04 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35031545
17.
Identification and evaluation of soft coral diterpenes as inhibitors of HIF-2α induced gene expression.
Bioorg Med Chem Lett;
21(7): 2113-5, 2011 Apr 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-21353547
18.
A new hypoxia inducible factor-2 inhibitory pyrrolinone alkaloid from roots and stems of Piper sarmentosum.
Chem Pharm Bull (Tokyo);
59(9): 1178-9, 2011.
Artigo
em Inglês
| MEDLINE
| ID: mdl-21881266
19.
Autocrine signaling by receptor tyrosine kinases in urothelial carcinoma of the bladder.
PLoS One;
16(7): e0241766, 2021.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34292953
20.
Correction: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer.
PLoS One;
16(12): e0261994, 2021.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34941969